Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2020-05-12 AGM Information
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Notice of 2020 Annual General Meeting and Form of Proxy
AGM Information Classification · 1% confidence The document explicitly states 'NOTICE OF THE 2020 ANNUAL GENERAL MEETING' and details the date, time, and location for the meeting. It includes a 'Letter from the Chairman' inviting shareholders, the formal 'Notice of the Annual General Meeting' containing Ordinary and Special Resolutions (including receiving accounts, re-electing directors, auditor appointment, and share allotment authorities), and notes on voting procedures via proxy. This content is characteristic of materials distributed for an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2020-05-12 English
Arix Bioscience Plc - Notice of Annual General Meeting
AGM Information Classification · 1% confidence The document is explicitly titled 'Arix Bioscience Plc - Notice of Annual General Meeting' and discusses the format, date, and proxy voting procedures for the 2020 Annual General Meeting (AGM). This directly relates to the materials shared concerning the AGM. Although it mentions that the Notice of the AGM was posted to shareholders and submitted to the National Storage Mechanism, the core content is the announcement and details of the meeting itself, making 'AGM Information' (AGM-R) the most appropriate classification over a simple 'Report Publication Announcement' (RPA), as it contains substantive meeting details rather than just announcing an attachment.
2020-05-12 English
Arix Bioscience Plc - Pharmaxis announces new data in myelofibrosis
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, reporting on an announcement made by its portfolio company, Pharmaxis Ltd. The content details clinical trial progress (Phase 1b data, advancement to Phase 2), safety profiles, and future development plans for a drug candidate (PXS-5505) targeting myelofibrosis. This structure—a company announcing positive clinical/pipeline updates, often referencing regulatory steps (like FDA IND submission) and future trial timelines—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on specific, material operational/clinical progress rather than just summarizing overall quarterly financial performance (which would be ER) or being a formal regulatory filing, it fits best as a general corporate announcement related to operations and pipeline. However, given the focus on clinical trial results and advancement, it is a significant operational update. It is not a full Annual Report (10-K), an Audit Report (AR), a Call Transcript (CT), or a formal Dividend Notice (DIV). It is a detailed announcement of clinical progress, which often overlaps with Earnings Releases (ER) but is more specific to R&D milestones. Since it is a press release announcing specific clinical data and pipeline progression, and not a summary of overall financial results, it is best classified as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a detailed press release that doesn't fit the specific financial report categories (10-K, IR, ER). However, if we consider the nature of the announcement—a significant operational/clinical update—it is often released alongside or in lieu of a formal Earnings Release (ER) if the period is not an official reporting quarter end, or it could be considered an Investor Presentation (IP) in spirit, but it is a text release, not a presentation deck. Given the context of reporting clinical trial progress and pipeline advancement, and since it is a press release format, 'RNS' (Regulatory Filings/General Announcement) is the safest classification when specific financial reporting codes don't apply, although 'ER' is often used for material operational news. I will lean towards RNS as it is a general press release format reporting material news that isn't strictly a financial summary.
2020-04-28 English
Arix Bioscience Plc - Harpoon doses first patient in multiple myeloma trial
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, noting an announcement from its portfolio company, Harpoon Therapeutics, regarding dosing the first patient in a clinical trial (HPN217) for multiple myeloma. This announcement includes details about triggering a $50 million milestone payment and provides the full text of Harpoon's original announcement. This type of communication, focusing on a specific operational/clinical development event and associated financial trigger, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal press release announcing a significant operational update (clinical trial initiation and milestone payment) rather than a comprehensive periodic financial report (like 10-K or IR), and it is not a transcript (CT) or a specific management/board change (MANG), it fits best as an Earnings Release (ER) which often includes key operational highlights that impact financials, or RNS as a general announcement. Given the focus on a clinical trial milestone payment, ER is a strong candidate, but since it's primarily a news announcement about a portfolio company's progress, RNS (Regulatory Filings/General Announcement) is often used for these types of non-periodic, material news updates that aren't strictly earnings figures. However, many companies use ER for significant operational milestones that trigger payments. Comparing the options, this is a material news announcement, not a full report. It is not a proxy statement (PSI), dividend notice (DIV), or director dealing (DIRS). Given the context of a press release announcing a clinical trial milestone payment, it aligns closely with the function of an Earnings Release (ER) which communicates key performance indicators and financial triggers, even if it's not the formal quarterly earnings report itself. If it were purely a regulatory filing without financial context, RNS would be better. Since it explicitly mentions a $50 million milestone payment, ER is the most appropriate classification for a material operational/financial update disseminated via PR Newswire.
2020-04-27 English
Arix Bioscience Plc - Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Arix Bioscience Plc - Director/PDMR Shareholding' and contains detailed tables labeled 'PDMR DEALING NOTIFICATION'. This notification structure details transactions by 'persons discharging managerial responsibilities' (PDMRs), including their name, position (Chief Operating Officer, Group Finance Director), the nature of the transaction ('Purchase of Ordinary Shares'), price, volume, and date. This content directly matches the definition for Director's Dealing (insider trades). Therefore, the appropriate filing type code is DIRS.
2020-04-17 English
Arix Bioscience Plc - Autolus announces FDA acceptance of IND application
Legal Proceedings Report Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, reporting on an announcement made by its portfolio company, Autolus Therapeutics plc. The core content is an update regarding the FDA's acceptance of an Investigational New Drug (IND) application for a product candidate (AUTO1) and subsequent plans for a pivotal study (AUTO1-AL1). This type of announcement, detailing clinical trial progress, regulatory milestones, and operational updates (like COVID-19 impact), is characteristic of communications aimed at investors regarding ongoing development activities. It is not a full financial report (10-K or IR), a transcript (CT), or a formal dividend/share change notice. It is a specific operational/development update. Since it is a press release announcing significant corporate/clinical news, it fits best under the general category for regulatory announcements that aren't strictly financial or governance-focused, or potentially an Investor Presentation (IP) if it were structured as slides, but as a news release, it aligns most closely with a general Regulatory Filing (RNS) or a specific type of investor communication. Given the nature of reporting clinical trial progress and regulatory acceptance, and lacking a more specific category like 'Clinical Trial Update', RNS serves as the appropriate general regulatory announcement category for this type of news release.
2020-04-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.